Compared to the healthy control group, we discovered that miR-340 was significantly lower expressed in BC patients (Figure 6D), miR-185 had no significantly differential expression in BC patients (Figure 6E), miR-20a and sE-cad levels were significantly highly increased in BC patients (Figures 6F, G). This evidence concerns the gene CAD and breast cancer.